Preprint Online!

Affinty Proteomics compatible with high-risk biological samples

We have posted a preprint titled “Plasma-treatment with the virucidal beta-propiolactone does not preclude analysis by large panel affinity proteomics, including the discovery of biomarker candidates” to medRxiv — find it here.

The work, which was performed with the support of SomaLogic, demonstrates the applicability of their SomaScan® platform (and likely other affinity proteomic approaches) to samples of high biological risk, as it remains largely effective even when input material has been exposed to the commonly used anti-viral treatment with beta-propiolactone.